On February 25, 2013, the U.S. Food and Drug Administration (FDA) closed the public comment period for the environmental assessment of the AquAdvantage Salmon. Their review of the first genetically modified animal for human consumption concluded with a “finding of no significant impact.” Numerous fishermen, consumer safety advocates, public health officials, ecologists, and risk assessment experts submitted comments that directly challenged this finding. Despite the opposition, it is very likely that the FDA’s approval of this genetically engineered salmon and precedent-setting regulatory process is imminent.… The aquaculture industry and corporate investors are championing this recent development in food biotechnology. They propose that this “invention” will yield ecological benefits, such as preserving wild salmon, while enhancing efficiency.… Unfortunately, the discussion of fisheries and oceans is constrained by ideological justifications that prevent a comprehensive assessment.… [The alternative approach presented here focuses on] how the logic of capital has shaped production and commodification processes. It also highlights how the most recent case of biotechnology in relation to salmon serves the needs of capital by increasing control of biological and ecological systems in order to better conform to economic dictates. The genetic modification of salmon is part of a biological speedup, whereby natural processes are transformed to achieve faster rates of return in the food marketplace.
This article can also be found at the Monthly Review website, where most recent articles are published in full.